← Russell 3000 cross-section

NTLA Intellia Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.9bn
Revenue TTM
$60m
Net income TTM
$-400m
Free cash flow
$-349m
Composite score
37.2
Sector rank
#1685

Valuation

P / E
EV / EBITDA
EV / sales
23.8
FCF yield
-18.81%
Earnings yield vs 10-yr
-26.31pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-672.2%
EBITDA margin
-696.4%
ROE
-55.0%
ROIC
-146.1%
Revenue growth
12.6%

Insider activity, last 90 days

Net open-market
$-0.51m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Comparison of Three Months Ended June 30, 2026 and 2025 The following table summarizes our results of operations: Collaboration Revenue Collaboration revenue decreased by $6.6 million during the three months ended June 30, 2026, as compared to the three months ended June 30, 2025. The decrease in collaboration revenue is primarily due to reductions in revenue under the 2016 Regeneron Agreement and the ATTR Co/Co. This increase is primarily related to increased legal expenses, compensation, and consulting costs associated with the continued buildout of a commercial function. …Intellia Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →